NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech, Inc. (Nasdaq: NKGN) today announced an online publication, titled "Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion" at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

GlobeNewswireMay 23 17:05 ET

10-Q: Quarterly report

SEC announcementMay 20 17:02 ET · Announcements

Top Midday Gainers

MultiMetaVerse Holdings (MMV) said Monday that it signed a non-binding term sheet to acquire 100% of Bowong Technology and its subsidiaries for an undisclosed amount. Shares surged 135% as intraday tr

MT NewswiresMay 20 14:00 ET

Trending Stocks Today: MultiMetaVerse Shoots up 136.96%

May 20th - US stocks trending in regular trading hours.Gainers: $MultiMetaVerse(MMV.US)$ shoots up 136.96% to $1.4 with a turnover of $192.18 million. $GT Biopharma(GTBP.US)$ surges 150.32% to $7.81 w

moomoo NewsMay 20 14:00 ET

Sector Update: Health Care Stocks Ease Monday Afternoon

Health care stocks were lower Monday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) rose

MT NewswiresMay 20 13:59 ET

Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.

BenzingaMay 20 13:28 ET